AKEBIA THERAPEUTICS, INC. analysts consensus, targets, ratings and recommendations | Nasdaq: AKBA | Nasdaq While Akebia Therapeutics, Inc. (NASDAQ:AKBA) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 15% in the last quarter.Despite this, the stock is a strong performer over the last year, no doubt about that. For the last week, the stock has had a daily average volatility of 7.30%. Volume fell during the last trading day despite gaining prices. Your losses are our losses too. 0 analysts 0%. On the downside, the stock finds support just below today's level from accumulated volume at $2.80 and $2.72. Twitter. Opinions of the stock are interesting as 5 analysts out of 8 who provided ratings for Akebia Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 3 rated it as “hold,” and 0 as “sell.” The average price from analysts is $6.71. During that time, it has gained 43%. Its lead product candidate is vadadustat, an oral therapy which has completed a Phase II study for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients; and clinical product candidate is ... Read more. 0 analysts 0%. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Akebia Therapeutics against related stocks people have also bought. Akebia Therapeutics biggest competitors are: To better understand Akebia Therapeutics performance you must compare its gains with other related stocks in same sector or industry.. For Akebia Therapeutics, the benchmark is made against Regeneron, Vertex Pharmaceuticals, Moderna, Seattle Genetics and Alexion Pharmaceuticals. AKBA stock news . At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Turning to the stock’s technical picture we see that short term indicators suggest on average that AKBA is a 50% Sell. Strong Buy. Analysts expect an earnings per-share of $-0.40, that is a 4.76% more than Q3. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Akebia Therapeutics share forecasts, stock quote and buy / sell signals below. Akebia Therapeutics (AKBA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). Akebia Therapeutics (NASDAQ:AKBA) was downgraded by investment analysts at BidaskClub from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Wednesday, BidAskClub reports. Should I buy or sell AKBA stock? Several other experts on Wall Street have posted such reports regarding the AKBA shares. Click here for a FREE analysis on AKBA. The other penny stock that has recorded significant gains in recent days is Akebia Therapeutics Inc (AKBA Stock Report). By. Please read the full disclaimer here. All successful traders recommend adhering to a trading strategy and not make decisions based on subjective opinions, rumors or feelings. Akebia Therapeutics holds several positive signals, but we still don't find these to be enough for a buy candidate. What Is Insider Buying? AKBA Stock Predictions. Buy, Sell Or Hold Akebia Therapeutics, Inc. (NASDAQ:AKBA) At $2.73? Needham rated the Akebia Therapeutics Inc. (NASDAQ: AKBA) stock “a Buy” and gave the company’s common stock a price target of $15. AKBA reported fiscal 3rd-quarter earnings of $-0.42 per share on revenue of $60.0 million. AKBA Stock Forecast - Is AKBA a buy or sell? In last trading session, Akebia Therapeutics, Inc. (NASDAQ:AKBA) saw 4,602,567 shares changing hands with its beta currently measuring 1.81. Nobody knows how much a stock will be priced in the future. Should I buy or sell AKBA? From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day! During the day the stock fluctuated 3.95% from a day low at $3.29 to a day high of $3.42. Shares of Akebia Therapeutics (NASDAQ:AKBA) had jumped 17.6% higher as of 11:42 a.m. EST on Friday, down from 21% earlier in the day. Should I buy or sell AKBA stock? The price is currently higher than the upper Bollinger band, which usually indicates a short-term correction. Akebia Therapeutics is part of the Healthcare sector and the Biotechnology industry, which contain 241 industry peers. Buy. According to fan-theory $4.56 will be the next possible trendtop level and thereby pose a resistance level which may not be broken on the first attempt. Needham rated the Akebia Therapeutics Inc. (NASDAQ: AKBA) stock “a Buy” and gave the company’s common stock a price target of $15. 22.77%. A breakdown below any of these levels will issue sell signals. The good news is that HC Wainwright just upgraded their price target on AKBA from $9 to $10, and keeps it's rating for AKBA as 'BUY'. Current Technical Analysis and interactive chart for $AKBA stock / shares. The Akebia Therapeutics stock is extremely overbought on RSI14 (80). Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Should I buy AKBA stock? Akebia Therapeutics (AKBA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy). The price has risen in 8 of the last 10 days and is up by 37.25% over the past 2 weeks. Price closed on Friday at $3.39 after exploding a 2.73%. Akebia Therapeutics Inc (AKBA) stock is trading at $2.79 as of 9:44 AM on Friday, Sep 4, an increase of $0.13, or 5.09% from the previous closing price of $2.65. AKBA Stock Predictions . The business has a 50 day simple moving average of $2.80 and a 200-day simple moving average of $8.37. The expected earnings per share for the stock is -$0.17. Penny Stocks To Buy [or Sell] #2: Akebia Therapeutics The other penny stock that has recorded significant gains in recent days is Akebia Therapeutics Inc (AKBA Stock Report). Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell stock in the company. setups and buypoints. Find out if you should buy AKBA stock. AKBA Buy or Sell? The AKBA stock forecast is provided by MarketClub with their Trade Triangle system. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. Long term indicators are suggesting an average of 50% Sell for it. Needham’s estimates were contained in a research note released on Thursday, November 14, 2019. 136,798 shares of the company were exchanged, compared to its average volume of 3,450,631. Some negative signals were issued as well, and these may have some influence on the near short-term development. That rank is influenced by a short-term technical score of 80. Official Close 11/27/2020 NAS. View Akebia Therapeutics, Inc. AKBA investment & stock information. The moment to sell your stock should always be determined by the stop-loss (automatic or manual), In the current situation of Akebia Therapeutics there is not any eligible sell setup, so Akebia Therapeutics stock holders with operations in green can keep their positions, In the last 30 days we couldn't find any rating for Akebia Therapeutics, Price levels above or below the Bollinger Bands signal that the price has followed a strong trend that has led to extreme upward or downward values. 1: Adjusted price after possible price splits or reverse-splits. Needham’s estimates were contained in a research note released on Thursday, November 14, 2019. None of the analysts rate the stock as a Sell, while none rate it as Overweight. All users should speak with their financial advisor before buying or selling any securities. 100% FREE. If you are a small investor you should not buy or sell based on these forecasts. featured in The Global Fintech Index 2020 as the top Fintech company of the country. We think it has very good upside potential if it can break around $16.60. Learn about AKBA with our data and independent analysis including price, star rating, valuation, dividends, and financials. If this is broken, then the next support from accumulated volume will be at $2.72 and $2.65. 22.31%. AKBA Stock Forecast - Is AKBA a buy or sell? View the real-time AKBA price chart on Robinhood and decide if you want to buy or sell commission-free. The Akebia Therapeutics stock is extremely overbought on RSI14 (89). In contrast, when we review AKBA stock’s current outlook then short term indicators are assigning it an average of 100% Sell, while medium term indicators are categorizing the stock at an average of 50% Sell. During the last day, the stock moved $0.13 between high and low, or 3.95%. Akebia Therapeutics Inc (AKBA) Q1 2020 Earnings Call Transcript Why Akebia Therapeutics Stock Is Crushing It Today 2 Small-Cap Stocks That Could Double Your Money View the real-time AKBA price chart on Robinhood and decide if you want to buy or sell commission-free. HC Wainwright is very positive to AKBA and gave it a "Buy" rating on October 26, 2020. AKBA Stock Predictions . An investment of $1,000USD on Mar 2014 would have a value of $148.03 nowadays. Top Penny Stocks To Buy [or sell] In October: Akebia Therapeutics Inc. First up on this list of penny stocks to watch is Akebia Therapeutics Inc. (AKBA Stock Report). On the reaction, there will be support on the roof of the current trend broken, which is $2.67, a level that may pose a second chance to hit a runner. Since then, AKBA stock declined by -85.20%. EPS for the same quarter last year was $-0.46. Find out now. A Stock must have an Opinion and a last month's Opinion. Real-time data provided for free by IEX. Pre-market Movers In … Plus, the 36-month beta value for AKBA is at 1.84. Strong Sell. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. This quarterly report represents an earnings surprise of -156%. At this point, the price is over the upper band, which should mean a near-term adjustment (at least) until it is under the band, The RSI broke out the oversold level of 30 on November 3 after just being in the oversold zone for a single day (what can be considered a strength signal). Sales resulted of $90.1 million in contrast to $74.2 million predicted by market consensus. "StockInvest.us" is a research service that provides financial data and technical analysis of publicly traded stocks. Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. What Is Insider Buying? Our recommended stop-loss: The Wall St estimate was $-0.17 per share on revenue of $84.9 million. 2 analysts 33.33%. Should I buy Akebia Therapeutics, Inc. (AKBA)? By using the site you agree and are held $3.23 The company that develops and commercializes renal therapeutics for patients who have kidney diseases. liable for your own investment decisions and agree to Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected. The price target was set to $10.00 - $9.00. The company has a current ratio of 2.15, a quick ratio of 1.67 and a debt-to-equity ratio of 0.24. AKBA stock traded up $0.05 during mid-day trading on Friday, hitting $2.52. According to present data Akebia Therapeutics's AKBA shares and potentially its market environment have been in bearish cycle last 12 months (if exists). Find out if you should buy AKBA stock. So far 1,934,118 shares have traded compared to average volume of 3,728,146 shares. Investors are just skittish right now. But it should be noted that it has been on a … So before you buy or sell Akebia Therapeutics, Inc. (NASDAQ:AKBA), you may well want to know whether insiders have been buying or selling. Should I buy or sell AKBA? Pinterest . A sell signal was issued from a pivot top point on Friday, October 16, 2020, and so far it has fallen -10.32%. Find out now with a free analysis on AKBA. Never miss a profitable trade. Find out whether AKBA is in an uptrend or down trend and how much momentum the trend has. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. Eric Enderson - November 19, 2020. Get the latest Akebia Therapeutics, Inc. AKBA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. A brief summary - strong Buy, Buy, strong Sell, Sell or Neutral signals for the Akebia Ther stock. Terms of Use and Privacy Policy. AKBA Stock Analysis - [Full Report] Free Signup: Advanced stock screener. Find the latest Akebia Therapeutics, Inc. (AKBA) stock quote, history, news and other vital information to help you with your stock trading and investing. The company has a current ratio of 2.15, a quick ratio of 1.67 and a debt-to-equity ratio of 0.24. They use their proprietary Smart Scan and Trade Triangle technology to analyze the stock and you will get an instant report on how AKBA will perform in the near future. Normally this may pose a good selling opportunity but since the stock has broken the trend up, the chance for a major correction due to high RSI is very small as the stock will find support at the trend broken. This might drive the stock higher in the near term. Users should not base their investment decision upon "StockInvest.us". Further fall is indicated until a new bottom pivot has been found. The stockhas broken the very wide and falling short-term trend up. Counting on Friday, it's been 4 consecutive sessions in green for Akebia Therapeutics. The RSI value on Friday was 65.13. Simple things usually work the best, In the current situation of Akebia Therapeutics there is not any eligible buy setup. The AKBA stock forecast is provided by MarketClub with their Trade Triangle system. Much like when we have to buy shares, determining when is appropiate time to sell is not a haphazard decision, and we must follow our own trading strategy. Akebia Therapeutics Inc Stock , AKBA. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares. So before you buy or sell Akebia Therapeutics, Inc. (NASDAQ:AKBA), you may well want to know whether insiders have been buying or selling. The consensus among analysts is that Akebia Therapeutics, Inc. (AKBA) is an Overweight stock at the moment, with a recommendation rating of 2.2. The stock acknowledged active focus on shares in the current trading session. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. WhatsApp. AKBA had a good upward run forming a fallen angel formation, and now after some consolidation it seems getting ready for a second run.It has a fair amount of insider buying going on. The stock should be watched closely. The stock climbed by as much as 22% on Friday. Given the investment horizon of 30 days, and your above-average risk tolerance our recommendation regarding Akebia Therapeutics is 'Strong Sell'.Macroaxis provides Akebia Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding AKBA positions. The average price we get from analysts is $18.00 which is $6.3 above current price. Several other experts on Wall Street have posted such reports regarding the AKBA shares. Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. Akebia Therapeutics, Inc. (NASDAQ: AKBA) The 36 Months beta value for AKBA stocks is at 1.25, while 6 of the analysts out of 7 who provided ratings for Akebia Therapeutics, Inc. stocks as a “buy” while 0 as overweight, 1 rated it as hold and 0 as sell. RTTNews 9d. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Add to watchlist Start Trading >> News More News. We think it has very good upside potential if it can break around $16.60. 100% FREE. Facebook. AKBA Stock Predictions. Market. AKBA | Complete Akebia Therapeutics Inc. stock news by MarketWatch. Get a free AKBA technical analysis report to make a better AKBA stock predictions on how the stock will perform in the near future. This stock may move much during a day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk".